Browse by Profession PharmaciesHospitalsDoctorsPatientsManufacturers

News for NPS

Named Patient Supply News

Healthcare Distribution Management Association (HDMA)

Masters Medical Inc (MMI) based in Florida is pleased to announce that it has become a member of the Healthcare Distribution Management Association (HDMA). This affliliation will provide additional resource to further strengthen the Masters supply chain and enhance the services we provide to our valued customers.

Masters, focused on providing the Patient, wherever they are, access to the best available treatments.

 
  
Master . . ,

Systemic Mastocytosis and Mast Cell Activation Syndrome - sodium cromoglicate 100mg Tablets

Masters Pharmaceuticals Ltd is pleased to announce the availability of sodium cromoglicate 100mg Tablets for the alleviation of the symptoms of Systemic Mastocytosis and Mast Cell Activation Syndrome.
Please see the information below regarding supply:

LORAZEPAM Injection 4mg/ml - Available from Masters Pharmaceuticals Limited.

Masters Pharmaceuticals Limited in the United Kingdom is pleased to announce the availability of Lorazepam Injection 4mg/mL.

Presentation: Lorazepam Injection 4mg/mL is supplied as 1mL vials in packs of 25

 

Information on Unlicensed Products: Mastocytosis

Mastocytosis is a rare disease that occurs in both children and adults. It is characterized by the presence of too many mast cells in connective tissues such as the skin, the lining of the stomach, intestine and other sites. Mast cells play a critical role in the immune system’s response to defend the body against infection and disease. 


Deflazacort - Providing crucial medicine for DMD Patients





Over the past few years many Doctors in the US, specialising in Child Neurology and Neuromuscular Disorders, have been prescribing Deflazacort for their patients with Duchenne’s Muscular Dystrophy. Deflazacort is a Glucocortoid (a class of steroid hormone) used as an anti-inflammatory and immunosuppressant.
 
As the product is still unlicensed in the US, Masters continues to work closely with several of these prescribing Doctors, in supplying Deflazacort to their patients.
 
Masters also continues to support the PPMD (Parent Project Muscular Dystrophy) with Annual Sponsorship, and since supplying Deflazacort to patients in the US, has established a strong relationship with the patients’ families.
More information on the PPMD can be found here: http://community.parentprojectmd.org
 
Deflazacort Treatment is available in the following strengths and packs:
 
Deflazacort 6mg Tablets - Pack of 20
Calcort 6mg Tablets - Pack of 60
Deflazacort  30mg Tablets - Pack of 10
Zamene Drops 22.75mg/ml - 13ml Pack

If you would like to place an order for Deflazacort, then please click here, and you will be taken directly to our ordering system. 


Vetoryl – Named Patient Supply for the Animal Patient


Masters has developed and built Dechra’s global Named Patient Supply for Vetoryl (trilostane), Dechra’s treatment for Cushing’s syndrome in dogs.
 
In 2004, Masters started supplying Vetoryl on a named patient basis to pet owners, veterinary hospitals and clinics in the US and licensed vets in the EU. The move was in response to several enquiries from pet owners in US asking whether we could obtain trilostane.
 
Masters generated more than $1 million in revenue for Dechra’s US business before local registration in January 2009. We continue to supply the 120mg version in the US, following EU registration and US registration of the 30mg and 60mg presentations.
 
In February 2008, we initiated a partnership with Endocrinovet in Sao Paulo, Brazil, to supply Vetoryl to Brazilian pet owners on a named patient basis. We have now expanded the business to Far East Asia, where demand for the treatment is continuing to grow.